restenosis

From Aaushi
Jump to navigation Jump to search

Introduction

The recurrence of a stenosis in a coronary artery.

Management

* average serum homocysteine lowered from 12 to 9 umol/L

# see trans-sulfuration pathway

Comparative biology

More general terms

References

  1. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004 Jun 24;350(26):2673-81. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15215483
  2. 2.0 2.1 Stone GW et al, TAXUS V ISR Investigators Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents. The TAXUS V ISR randomized trial. JAMA 2006; 295:1253 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16531618
    Holmes DR Jr et al, SISR Investigators Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents. The SISR randomized trial. JAMA 2006; 295:1264 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16531619
    Mukherjee D and Moliiterno DJ Brachytherapy for in-stent restenosis: A distant second choice to drug-eluting stent placement. JAMA 2006; 295:1307 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16531620
  3. 3.0 3.1 Deuse T et al. Dichloroacetate prevents restenosis in preclinical animal models of vessel injury. Nature 2014 May 29; 509:641 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24747400 <Internet> http://www.nature.com/nature/journal/v509/n7502/full/nature13232.html